Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.54 |
| ▸ | BCL2 | P10415 | 11/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 4/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138153 | 0.83 | HTR7 (0.50) | HTR7BCL2BAK1BCL2L1KDM4E | |
| Hydrochloric Acid SCHEMBL1138333 | 0.82 | HTR7 (0.49) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL1137923 | 0.81 | HTR7 (0.54) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL1138132 | 0.79 | HTR7 (0.47) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL5857768 | 0.79 | SIGMAR1 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL5857769 | 0.79 | SIGMAR1 (0.50) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1138155 | 0.78 | HTR7 (0.47) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL8744977 | 0.78 | KDM4E (0.57) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL1138558 | 0.77 | HTR7 (0.46) | HTR7BCL2BAK1BCL2L1KDM4E | |
| SCHEMBL2193164 | 0.77 | ALDH1A1 (0.61) | HTR7BCL2BAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487810-B9 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2011-02-23 | — | — | EP | disclosed |
| EP-1487810-B1 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-02-17 | — | — | EP | disclosed |
| US-7297697-B2 | with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | NPY2R, NPY1R, CBR3 | HTR7 776/4885BCL2 1903/4885BAK1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.